SCHEMBL5041168

SCHEMBL5041168

COC(C(=O)O)c1cc(C(F)(F)F)ccc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.46
TDO2 P48775 1/20 0.46
PPARG P37231 4/20 0.43
PDE2A O00408 3/20 0.43
AKR1C3 P42330 3/20 0.41
AKR1C2 P52895 3/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CFTR P13569 1/20 0.40
CYP2C19 P33261 2/20 0.39
USP2 O75604 1/20 0.39
MEN1 O00255 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CTSA P10619 1/20 0.38
APP P05067 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5042110 0.88 PDE2A (0.54) PPARGPDE2AAKR1C3AKR1C2KDM4E
SCHEMBL5038641 0.82 CES2 (0.46) PPARGPDE2AAKR1C3AKR1C2KDM4E
SCHEMBL5041933 0.80 ALDH1A1 (0.38) PPARGAKR1C3AKR1C2KDM4EALDH1A1
SCHEMBL24223271 0.79 FFAR4 (0.41) PDE2A
SCHEMBL2349189 0.78 AKR1C3 (0.43) AKR1C3AKR1C2KDM4ECYP2C19MEN1
SCHEMBL5041566 0.78 ALDH1A1 (0.50) PPARGKDM4EALDH1A1PPARA
SCHEMBL6400520 0.78 PDE2A (0.47) IDO1TDO2PPARGPDE2AAKR1C3
SCHEMBL6400526 0.78 PDE2A (0.47) IDO1TDO2PPARGPDE2AAKR1C3
SCHEMBL6400522 0.78 PDE2A (0.47) IDO1TDO2PPARGPDE2AAKR1C3
SCHEMBL20873860 0.76 PPARG (0.49) PPARGAKR1C3AKR1C2PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 IDO1 742/4885TDO2 1268/4885PPARG 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.